Detalhe da pesquisa
1.
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
Pediatr Blood Cancer
; 64(8)2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28409853
2.
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Nature
; 478(7370): 524-8, 2011 Aug 03.
Artigo
Inglês
| MEDLINE | ID: mdl-21814200
3.
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).
Pediatr Blood Cancer
; 62(10): 1717-24, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25976292
4.
Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice.
Oncotarget
; 9(82): 35313-35326, 2018 Oct 19.
Artigo
Inglês
| MEDLINE | ID: mdl-30450160
5.
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Clin Cancer Res
; 22(16): 4014-22, 2016 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26920889
6.
POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
Oncotarget
; 6(31): 30902-18, 2015 Oct 13.
Artigo
Inglês
| MEDLINE | ID: mdl-26360610
7.
Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Oncotarget
; 5(19): 8947-58, 2014 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25333254
8.
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.
Exp Hematol
; 42(2): 101-13.e5, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24184354
9.
Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Mol Cancer Res
; 11(9): 1004-16, 2013 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-23754844